Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Symbol
- CRL
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $13.85B
- 52 week range
- 146.2 - 303.31
Valuation
- Share price
- $290.19 (close of 2026-10-02)
- P/E (TTM)
- -60.46x
- Price to book
- 4.87x
- Price to free cash flow
- 37.37x
- Enterprise value
- $16.69B
- Book value per share
- $59.63
Price performance
| Period | Change |
|---|---|
| 1 day | +1.17% |
| 5 days | -0.90% |
| 1 month | -0.54% |
| 3 months | +25.79% |
| 6 months | +66.88% |
| Year to date | +45.47% |
| 1 year | +65.48% |
| 3 years | +50.05% |
| 5 years | -30.36% |
| 10 years | +248.20% |
| All time | +1219.05% |
Members of Congress who disclosed CRL trades
Jefferson Shreve · Robert Bresnahan · Julie Johnson
Super investors holding CRL
Bill Nygren (Harris Associates LP) · John Rogers (Ariel Investments LLC) · Ken Griffin (Citadel)
Profitability and growth
- Return on equity
- -4.55%
- Return on invested capital
- 0.23%
- Return on assets
- -2.02%
- Return on capital employed
- 0.42%
- Gross margin
- 19.13%
- Net margin
- -3.59%
- EBITDA margin
- 10.67%
- Revenue growth
- -0.85%
- Net income growth
- -750.08%
- Free cash flow growth
- 3.37%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 2.68%
- Current ratio
- 1.35x
- Net debt to EBITDA
- 12.86x
Latest reported year
- Period end
- 2025-12-27
- Fiscal year
- 2025
- Revenue
- $4.02B
- Cost of revenue
- $3.25B
- Gross profit
- $768.24M
- EBITDA
- $428.47M
- Net income
- -$144.34M
- Earnings per share
- $-2.91
- Shares outstanding
- 49.56M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-27 | $4.02B | $768.24M | -$144.34M | $-2.91 |
| 2024-12-28 | $4.05B | $978.35M | $22.20M | $0.20 |
| 2023-12-30 | $4.13B | $1.37B | $474.62M | $9.27 |
| 2022-12-31 | $3.98B | $1.32B | $486.23M | $9.57 |
| 2021-12-25 | $3.54B | $1.21B | $390.98M | $7.77 |
| 2020-12-26 | $2.92B | $961.66M | $364.30M | $7.35 |
| 2019-12-28 | $2.62B | $868.77M | $252.02M | $5.17 |
| 2018-12-29 | $2.27B | $775.24M | $226.37M | $4.72 |
| 2017-12-30 | $1.86B | $1.57B | $123.36M | $2.60 |
| 2016-12-31 | $1.68B | $1.40B | $154.76M | $3.29 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-27 | 19.13% | -3.59% | -4.55% | 0.23% |
| 2024-12-28 | 24.16% | 0.55% | 0.64% | 2.66% |
| 2023-12-30 | 33.06% | 11.49% | 13.18% | 8.08% |
| 2022-12-31 | 33.10% | 12.23% | 16.31% | 8.91% |
| 2021-12-25 | 34.17% | 11.04% | 15.40% | 19.46% |
| 2020-12-26 | 32.89% | 12.46% | 17.20% | 16.36% |
| 2019-12-28 | 33.14% | 9.61% | 15.39% | 18.80% |
| 2018-12-29 | 34.21% | 9.99% | 17.15% | 9.58% |
| 2017-12-30 | 84.41% | 6.64% | 11.78% | 7.30% |
| 2016-12-31 | 83.52% | 9.20% | 18.44% | 8.84% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-27 | $213.77M | - |
| 2024-12-28 | $194.61M | - |
| 2023-12-30 | $276.77M | - |
| 2022-12-31 | $233.91M | - |
| 2021-12-25 | $242.28M | - |
| 2020-12-26 | $229.45M | - |
| 2019-12-28 | $238.96M | - |
| 2018-12-29 | $196.33M | $1.63B |
| 2017-12-30 | $192.28M | $1.09B |
| 2016-12-31 | $121.40M | $1.19B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-27 | $518.49M | $71.08M |
| 2024-12-28 | $501.61M | $69.89M |
| 2023-12-30 | $365.37M | $72.05M |
| 2022-12-31 | $294.91M | $73.62M |
| 2021-12-25 | $532.03M | $71.47M |
| 2020-12-26 | $380.01M | $56.34M |
| 2019-12-28 | $340.42M | $57.27M |
| 2018-12-29 | $301.09M | $47.35M |
| 2017-12-30 | $235.64M | $44.00M |
| 2016-12-31 | $261.61M | $43.64M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $2.97
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-05 | Jun/2026 | $2.72 |
| 2026-05-07 | Mar/2026 | $1.96 |
| 2026-02-18 | Dec/2025 | $2.33 |
| 2025-11-05 | Sep/2025 | $2.32 |
| 2025-08-06 | Jun/2025 | $2.50 |
| 2025-05-07 | Mar/2025 | $2.06 |
| 2025-02-19 | Dec/2024 | $2.50 |
| 2025-02-12 | - | - |
Filings and sources
- Company website
- criver.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
ICON plc (ICLR) · Revvity, Inc. (RVTY) · Medpace Holdings, Inc. (MEDP) · Labcorp Holdings Inc. (LH) · Quest Diagnostics Inc (DGX) · Eli Lilly & Co (LLY) · Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades